Tegoprazan R-Isomer
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

942195-56-4Tegoprazan R-Isomer

● In Stock

Catalogue No.:VE0028660
CAS No.:942195-56-4
Mol. Formula:C20H19F2N3O3
Mol. Weight:387.4 g/mol

Additional information on CAS 942195-56-4

Parent drug

Tegoprazan

IUPAC Name

(R)-7-((5,7-Difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-5-carboxamide

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(C1=CC(O[C@@H]2CCOC3=C2C(F)=CC(F)=C3)=C4NC(C)=NC4=C1)N(C)C

InChI

InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m1/s1

Description

Tegoprazan R-Isomer, CAS 942195-56-4, is the enantiomeric impurity associated with the potassium-competitive acid blocker tegoprazan. With molecular formula C20H19F2N3O3 and molecular weight 387.4 g/mol, it represents stereochemical nonconformity rather than a structural degradant. Such isomeric impurity can arise from asymmetric synthesis, epimerization at a chiral precursor, or incomplete enantiomeric resolution during manufacture. Regulatory assessment typically focuses on enantiomeric purity, because pharmacological divergence between isomers may affect potency and exposure. Determination commonly requires chiral LC methods, often complemented by LC-MS/MS for trace profiling and quantitative confirmation.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url